Market Research Report
Acute Myeloid Leukemia Pricing, Reimbursement, and Access
|Published by||Datamonitor Healthcare||Product code||603963|
|Published||Content info||132 Pages
Delivery time: 1-2 business days
|Acute Myeloid Leukemia Pricing, Reimbursement, and Access|
|Published: December 15, 2017||Content info: 132 Pages||
The level of concern surrounding the budget impact of acute myeloid leukemia (AML) has traditionally been low due to the relatively small size of the population in comparison to solid tumors, the high severity of the disease, and a lack of branded treatment options. As a result, few access controls are utilized for AML therapies. However, with several AML medications recently gaining approval, and many more in the late-stage pipeline, many interviewed payers express concern about the potentially growing budget impact of the indication in the future.
A considerable proportion of the recently approved and pipeline AML treatments are mutationally targeted, and despite their smaller target patient populations, are anticipated to contribute heavily to the increasing cost of therapy. Payers and key opinion leaders also highlight the likelihood of treatment with combinations of targeted therapies in the future, further increasing the level of payer concern. Due to the rising expenditure, payer acceptance will become more critical for the commercial success of new AML therapies. This analysis examines payer views on recently approved and pipeline AML agents, the tools used to moderate budget impact, and changing evidentiary requirements.